首页 › 滤泡性淋巴瘤 › 明尼苏达州 › Rochester
Rochester MN 滤泡性淋巴瘤临床试验
10项针对 滤泡性淋巴瘤的研究正在 Rochester及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本(英文)
正在为研究招募参与者?将此页面置顶展示 — $99 / 30天 →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
招募中1/2 期
- Mayo Clinic Rochester, Rochester
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
招募中1/2 期
- Research Site, Rochester
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
招募中1 期
- Mayo Clinic - Rochester, Rochester
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
招募中1 期
- Mayo Clinic - Rochester, Rochester
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
招募中2 期
- Research Site, Rochester
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
招募中3 期
- Mayo Clinic - Rochester, Rochester
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
招募中1/2 期
- Mayo Clinic, Clinical Trials Referral Office, Rochester
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
招募中1/2 期
- Mayo Clinic in Rochester, Rochester
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
招募中1/2 期
- Mayo Clinic, Rochester
Q702 for the Treatment of Patients With Hematologic Malignancies
招募中1 期
- Mayo Clinic in Rochester, Rochester
其他城市的 滤泡性淋巴瘤试验
- New York City, NY24 项研究
- Milwaukee, WI19 项研究
- Nashville, TN18 项研究
- Houston, TX18 项研究
- Boston, MA17 项研究
- Baldwin Park, CA16 项研究
- Seattle, WA15 项研究
- Durham, NC15 项研究
- Salt Lake City, UT13 项研究
- Columbus, OH13 项研究
- Chicago, IL12 项研究
- San Antonio, TX12 项研究
Rochester的其他研究
- 乳腺癌42 项研究
- 非小细胞肺癌37 项研究
- 转移性癌症31 项研究
- 癌症(所有类型)30 项研究
- 卵巢癌29 项研究
- 结直肠癌29 项研究
- 多发性骨髓瘤24 项研究
- 心力衰竭22 项研究
- 前列腺癌22 项研究
- 胰腺癌22 项研究
- 子宫内膜癌20 项研究
- 肺癌20 项研究
数据来自 ClinicalTrials.gov,检索日期:2026年10月6日。每项研究自行设定入选标准,由研究团队决定谁能参与。